INTRODUCTION
============

The circadian time-keeping system evolved from cyanobacteria to humans, and drives circadian rhythm over a 24-h period to anticipate and respond to environmental changes in accordance with sunrise and sunset. Molecular clocks, found in nearly all tissues, are organized in a hierarchical system, with the master clock located in the hypothalamic suprachiasmatic nucleus (SCN) of the anterior hypothalamus and local clocks located in both extra-SCN brain regions and peripheral organs. The master clock synchronizes the internal timing of peripheral clocks to drive circadian control of physiology and behavior.

Chronic disturbances in circadian rhythmicity in patients with mood disorders were noted over 50 years ago ([@b72-molce-40-7-450]). Patients with mood disorders, including major depressive disorder (MDD), bipolar disorder (BPD), and seasonal affective disorder (SAD), exhibit disrupted circadian rhythmicity in body temperature, hormone secretions, e.g., cortisol and melatonin, blood pressure, and sleep-wake cycles ([@b4-molce-40-7-450]; [@b72-molce-40-7-450]). Human genetic and animal studies have shown molecular links between circadian rhythm and mood disorders ([@b48-molce-40-7-450]). The central neurotransmitter system has been implicated in mood regulation via a variety of biochemical and signal transduction processes ([@b49-molce-40-7-450]; [@b59-molce-40-7-450]). Identification of molecular clockwork components has provided a link between the circadian clock and the monoamine system ([@b5-molce-40-7-450]).

There is an association between circadian rhythm and emotional regulation in neurodegenerative diseases, such as Parkinson's disease (PD) ([@b74-molce-40-7-450]). PD is characterized by progressive degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc), leading to motor dysfunction ([@b22-molce-40-7-450]). Patients with PD also display non-motor and circadian rhythm-related symptoms, such as mood dysregulation, specifically depression, anxiety, and apathy ([@b18-molce-40-7-450]; [@b66-molce-40-7-450]). However, the etiology of mood disorders in PD has not been elucidated, and drug development has been limited ([@b1-molce-40-7-450]). We review the literature concerning mood regulation in healthy and PD states from a chronobiological view.

MAMMALIAN CIRCADIAN CLOCK
=========================

The mammalian circadian clock is a hierarchical time-keeping system. The master clock, which acts as the circadian pacemaker, is located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus. Local clocks exist in extra-SCN brain regions and peripheral organs ([@b7-molce-40-7-450]; [@b76-molce-40-7-450]). The master clock synchronizes internal clock timing to external photic zeitgebers from light input via the retina, and peripheral clocks mediate circadian control of physiology and behavior by adjustment from the SCN via endocrine and systemic cues ([@b23-molce-40-7-450]).

The daily timing of physiological processes is influenced by peripheral oscillators. Transcriptome-profiling supports this notion; more than 10% of total mRNA shows circadian expression patterns in the liver ([@b3-molce-40-7-450]; [@b64-molce-40-7-450]; [@b80-molce-40-7-450]). By comparing the degree of circadian regulation in different tissues, it has been shown that most circadian gene transcripts are expressed in a tissue-specific manner, and that the circadian phase of gene transcripts is distinct ([@b53-molce-40-7-450]; [@b64-molce-40-7-450]).

The circadian clock consists of a network of transcription-translation feedback loops that generate endogenous circadian rhythm. In the core feedback loop, the positive elements include members of the basic helix-loop-helix (bHLH)-PAS (Period-ARNT-Single-minded) domain-containing transcription factor family, CLOCK (or NPAS), and BMAL1 ([@b15-molce-40-7-450]; [@b39-molce-40-7-450]). CLOCK and BMAL1 heterodimerize and activate transcription of target genes containing E-box *cis*-regulatory enhancer sequences in their promoter regions, such as *Periods* (*Per1*, *Per2,* and *Per3*) and *Cryptochromes* (*Cry1* and *Cry2*) ([@b28-molce-40-7-450]). Negative feedback is achieved by PER:CRY heterodimers that translocate to the nucleus to repress their own expression by inhibiting CLOCK:BMAL1 heterodimer activity ([@b42-molce-40-7-450]; [@b60-molce-40-7-450]).

Another regulatory loop controls *Bmal1* expression through competitive binding of two retinoic acid-related orphan nuclear receptors, REV-ERBα and RORα, to retinoic acid-related orphan receptor response elements (ROREs) in the *Bmal1* promoter. While RORα induces *Bmal1* transcription, REV-ERBα represses *Bmal1* expression ([@b31-molce-40-7-450]; [@b54-molce-40-7-450]) through the recruitment of co-repressor N-CoR and histone deacetylase3 (HDAC3) ([@b77-molce-40-7-450]). Extensive post-translational modifications of core clock proteins also provide fine tuning of circadian clock system by controlling their stability, nuclear localization, and activity ([@b27-molce-40-7-450]).

Under pathological conditions, decreased circadian amplitude -- the difference between peaks and troughs of circadian rhythms -- is often observed ([@b29-molce-40-7-450]). Rev-erb α is a key molecule for determining amplitude. F-box protein FBX7 ubiquitinates and degrades phosphorylated REV-ERBα by cyclin-dependent kinase 1 (CDK1) to regulate clock amplitude ([@b81-molce-40-7-450]). ROR promotes chromatin decondensation during the activation phase of the circadian cycle to facilitate REV-ERB binding to open chromatin during the inactivation phase to maintain circadian amplitude ([@b84-molce-40-7-450]).

CIRCADIAN DYSFUNCTION AND MOOD DISORDERS
========================================

Patients with mood disorders often display abnormal rhythmicity of body temperature, cortisol and melatonin levels, blood pressure, and sleep/wake cycles suggesting circadian rhythm disruption ([@b72-molce-40-7-450]). Sundown syndrome, also referred to as "nocturnal delirium," is characterized by worsening of behaviors such as agitation, aggression, restlessness, and delirium, particularly during the late afternoon/early evening, implying a strong association between circadian rhythm and mood regulation ([@b9-molce-40-7-450]). Genome-wide association studies have identified circadian gene polymorphisms that influence psychiatric disease susceptibility. These circadian gene variants include *CLOCK*, *BMAL1*, *PER3*, and *REV-ERBα,* which are associated with BPD, MDD, and SAD ([@b41-molce-40-7-450]; [@b47-molce-40-7-450]; [@b62-molce-40-7-450]). Moreover, a transcriptome-wide analysis of postmortem brains from patients with MDD revealed weaker circadian gene expression and disrupted phase relationships between individual clock genes ([@b45-molce-40-7-450]).

Several animal studies support the influence of circadian clock genes on mood regulation in brain regions implicated in emotion. *Clock*Δ19 mice, which harbor *Clock* gene mutations, exhibit mania-like behavioral patterns, similar to those in BPD, including hyperactivity, increased cocaine sensitization, decreased depression, anxiety-like behaviors, and decreased sleep latency ([@b26-molce-40-7-450]; [@b50-molce-40-7-450]; [@b58-molce-40-7-450]). *Clock*Δ19 mice display enhanced ventral tegmental area (VTA) DAergic cell firing and bursting ([@b50-molce-40-7-450]). Viral delivery of a functional *Clock* gene into the VTA rescues mania-like behaviors ([@b58-molce-40-7-450]), suggesting that manipulation of CLOCK activity in the VTA DAergic system regulates mood. *Per1* knockout mice ([@b83-molce-40-7-450]) and *Per2^Brdm1^* mice (*Per2* mutant mice harboring a deletion in the PAS domain) ([@b82-molce-40-7-450]) exhibit different sensitivities to cocaine administration, indicating abnormalities in the reward circuit. *Per1* mutant mice show lack of sensitization, while *Per2* mutant mice display hypersensitization to cocaine compared to wild-type mice ([@b2-molce-40-7-450]). *Per2^Brdm1^* mice exhibit a less depressive-like phenotype in despair-based tests. The phenotype is associated with increased DA levels in the mesolimbic DAergic circuit via reduced monoamine oxidase A (MAOA) activity, which plays an important role in dopamine metabolism ([@b33-molce-40-7-450]).

In the midbrain, the circadian nuclear receptor REV-ERBα is a crucial modulator of mood-related behaviors ([@b20-molce-40-7-450]). *Rev-erbα*-deficient mice exhibit mania-like behaviors characterized by decreased anxiety, a depressive-like phenotype, hyperactivity, increased risk-taking, and augmented aggression. Pharmacological inhibition of REV-ERB activity, specifically in the ventral midbrain, induces similar behavioral patterns and hyperdopaminergic states. REV-ERB α directly represses tyrosine hydroxylase (*TH*) expression, which is a rate-limiting enzyme for DA biosynthesis, through competition with nuclear receptor-related 1 protein (NURR1; an essential nuclear receptor for DAergic neuronal function). This interaction produces the circadian rhythmicity of the DAergic system. REV-ERBα inhibits *TH* gene expression through HDAC3 recruitment and histone acetylation regulation according to the circadian rhythm. These mechanisms contribute to the circadian nature of the DAergic system and mood regulation ([Fig. 1](#f1-molce-40-7-450){ref-type="fig"}).

MIDBRAIN DOPAMINERGIC NEURONAL CIRCUIT AND FUNCTION
===================================================

Mood is controlled by complex neural circuits and various neurotransmitters. Many brain regions that contribute to mood, including the hippocampus, prefrontal cortex (PFC), VTA, nucleus accumbens (NAc), amygdala, hypothalamus, and lateral habenula, interact with each other via circuits in the DAergic, noradrenergic, serotonergic, glutamatergic, and GABAergic pathways ([@b52-molce-40-7-450]).

The DAergic system is implicated in mood regulation ([@b20-molce-40-7-450]; [@b33-molce-40-7-450]; [@b58-molce-40-7-450]). DAergic neurons in the VTA innervate the PFC and the NAc, which are referred to as the mesocortical and mesolimbic pathways, respectively. The mesocorticolimbic pathway is important for the control of motivation, emotion, and reward functions ([@b55-molce-40-7-450]; [@b73-molce-40-7-450]; [@b75-molce-40-7-450]). Abnormalities in this circuit induce addiction, affective disorders, schizophrenia, and attention-deficit hyperactive disorder ([@b30-molce-40-7-450]; [@b36-molce-40-7-450]; [@b67-molce-40-7-450]). The nigrostriatal pathway from the substantia nigra (SN) to dorsal striatum (also known as the caudate-putamen) is another DAergic pathway associated with motor function; degeneration of this circuit can induce PD ([@b19-molce-40-7-450]).

DAergic neurons in the SN and VTA have distinct anatomical, molecular, and electrophysiological characteristics, though some projection patterns have been shown to overlap ([@b13-molce-40-7-450]). Few DAergic projections originating from the SN innervate the ventral striatum, while some VTA projections innervate the dorsal striatum. DAergic projections to the amygdala and PFC come from both SN and VTA ([@b10-molce-40-7-450]). The SN and VTA receive afferent inputs from brain regions involved in mood regulation, such as the central amygdala and dorsal raphe ([@b68-molce-40-7-450]). Based on the partially shared input-output networks, we speculate that the functions of the SN and VTA may not be mutually exclusive.

Notably, both the SN and VTA harbor functional clockwork, and the key activities of these regions oscillate in a circadian manner. Core clock genes, including *Bmal1, Per2* and *Rev-erbα,* in the ventral midbrain exhibit robust circadian oscillations ([@b20-molce-40-7-450]). TH expression is also circadian ([@b20-molce-40-7-450]; [@b69-molce-40-7-450]; [@b70-molce-40-7-450]). Additionally, the electrophysiological activities of the VTA demonstrate a robust diurnal pattern ([@b24-molce-40-7-450]; [@b46-molce-40-7-450]). These suggest that SN and VTA function are under circadian rhythm control.

CIRCADIAN DISRUPTION AND MOOD DISORDERS IN PARKINSON'S DISEASE
==============================================================

PD is a neurodegenerative disorder that results from DAergic neuronal death in the SNpc ([@b22-molce-40-7-450]), resulting in motor deficits as well as non-motor symptoms, such as mood dysregulation. DAergic neuron degeneration is more concentrated in the SNpc ventral tier than the SNpc dorsal tier and VTA, suggesting that SN and VTA DAergic neurons have different susceptibilities to degeneration in PD ([@b13-molce-40-7-450]). Ventral SNpc DAergic neurons innervate not only the striatum ([@b17-molce-40-7-450]) but also the PFC ([@b10-molce-40-7-450]), which is implicated in PD with depression ([@b1-molce-40-7-450]). Thus, the SNpc ventral tier may be implicated in both the motor and non-motor symptoms of PD. Approximately 45% of patients with PD experience depression ([@b16-molce-40-7-450]; [@b18-molce-40-7-450]), and 50% have comorbid anxiety ([@b14-molce-40-7-450]). Although the etiology of mood disorders in PD is unclear, dysfunctional monoaminergic neurotransmission is widely observed ([@b12-molce-40-7-450]; [@b32-molce-40-7-450]; [@b79-molce-40-7-450]). However, direct evidence for the contribution of serotonin to mood disturbances in PD is lacking ([@b44-molce-40-7-450]). Selective serotonin reuptake inhibitors (SSRIs), classic antidepressants, lack efficacy in patients with PD ([@b71-molce-40-7-450]). Levodopa (L-DOPA) treatment, a well-known antiparkinsonian drug, does not improve anxiety and depression in patients with PD ([@b38-molce-40-7-450]; [@b56-molce-40-7-450]). Pramipexole (DA agonist) and nortriptyline (tricyclic antidepressant that acts as a serotonin and norepinephrine reuptake inhibitor but has side effects) are the only effective drugs for depression in PD ([@b1-molce-40-7-450]). Therefore, therapeutic approaches that control the upstream regulators of the DA system, such as REV-ERBα, may hold promise.

Local inhibition of REV-ERBα activity by injection of a potent REV-ERBα antagonist SR8278 ([@b40-molce-40-7-450]) into the ventral midbrain induces a hyperdopaminergic state, caused by disappearance of REV-ERBα repression of TH expression. SR8278-injected mice also exhibit mania-like behaviors, including decreased depressive- and anxiety-like phenotypes at dusk, leading to disappearance of the circadian pattern of mood-related behaviors ([@b20-molce-40-7-450]; [Fig. 2A](#f2-molce-40-7-450){ref-type="fig"}). Conversely, 6-hydroxydopamine (6-OHDA)-injected mice (animal model of PD) exhibit a hypodopaminergic state owing to DAergic neuronal death in the SNpc and increased depressive and anxiety-like phenotypes at dawn, resulting in disruption of the circadian pattern of mood-related behaviors (unpublished data: [Fig. 2A](#f2-molce-40-7-450){ref-type="fig"}). Changes in mood-related behaviors in SR8278- and 6-OHDA-injected animals can be dissociated from locomotor dysfunction. SR8278-infused mice show an array of mania-like behaviors that cannot be attributed to increased locomotion ([@b20-molce-40-7-450]). Mice injected unilaterally with 6-OHDA intrastriatally exhibit motor coordination problems, though not regarding voluntary locomotion ([@b34-molce-40-7-450]; [@b57-molce-40-7-450]). These suggest that appropriate circadian oscillation of DA levels is necessary to elicit circadian mood-related behaviors ([Fig. 2B](#f2-molce-40-7-450){ref-type="fig"}).

Mood disorder, which is often accompanied by sundown syndrome, and disruption of circadian rhythmicity are both common in neurodegenerative diseases, including Alzheimer's disease (AD) and PD ([@b11-molce-40-7-450]; [@b74-molce-40-7-450]). Clinical studies have shown disrupted rest-activity cycles, changes in blood pressure and heart rate rhythm, abnormal hormone secretion, and non-motor symptoms in PD ([@b65-molce-40-7-450]). Conversely, circadian abnormalities in PD may also influence pathological processes, e.g., circadian disruption exacerbates motor deficits and DAergic neuronal loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of PD ([@b43-molce-40-7-450]). Circadian clock protein deficiency leads to vulnerability to oxidative injury and neurodegeneration in various animal models ([@b51-molce-40-7-450]). Thus, the mechanisms linking molecular clocks and various non-motor symptoms and neurodegeneration in PD should be investigated further. Clock-targeted therapeutics might be beneficial for treating neurodegenerative diseases.

CONCLUSIONS
===========

We reviewed the role of the circadian clock in mood-related behaviors in healthy and pathological states. Pharmacological treatments to improve mood disorders, such as SSRIs, lithium, or valproic acid, shift the phase or modulate the circadian rhythm period ([@b37-molce-40-7-450]; [@b49-molce-40-7-450]; [@b63-molce-40-7-450]). Lithium, a mood stabilizer used to treat BPD, inhibits glycogen synthase kinase-3 beta (GSK3β), which phosphorylates and stabilizes REV-ERBα ([@b78-molce-40-7-450]). REV-ERBα influences mood regulation through circadian control of the DAergic system ([@b20-molce-40-7-450]), suggesting that REV-ERBα is a potential therapeutic target for PD with comorbid mood disorders. Small molecules targeting the molecular clock, e.g., a synthetic antagonist of REV-ERB ([@b40-molce-40-7-450]), are being evaluated. REV-ERB agonists alter circadian gene expression in various peripheral tissues and brain regions, and cause diverse physiological changes, especially in sleep architecture and emotional behaviors in mice ([@b8-molce-40-7-450]; [@b61-molce-40-7-450]). Future studies should characterize the mechanisms of diverse clock-targeting molecules that have therapeutic potential for treating clock-related diseases.

While we mainly highlighted the contribution of the DAergic system to the circadian rhythm of mood regulation and its implication in mood disorders accompanied with PD, we cannot rule out the contribution of other brain circuits. For example, the lateral preoptic area and paraventricular nucleus are enriched with DAergic neurons regulated by photoperiods ([@b25-molce-40-7-450]). The lateral habenula may act as a link between the circadian DAergic system and daily mood regulation in terms of regulating DA release through projections to the SN and VTA ([@b35-molce-40-7-450]). Other candidates include the bed nucleus of the stria terminalis, central amygdala, basolateral amygdala, dentate gyrus, and paraventricular thalamic nucleus ([@b6-molce-40-7-450]; [@b21-molce-40-7-450]). Therefore, it is important to understand the role of circadian rhythm in other neuronal circuits and brain regions involved in mood regulation.
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![Circadian rhythm molecular networks in midbrain DAergic neurons and mood regulation\
Circadian *Bmal1* expression is regulated by competitive binding of REV-ERBs and RORs to RRE in the *Bmal1* promoter. RRE, the *cis*-element recognized by the circadian nuclear receptor REV-ERBα, overlaps with NBRE, which is recognized by the nuclear receptor NURR1 in the *TH* promoter. REV-ERBα antagonizes NURR1-induced activation of the *TH* promoter via binding to RRE/NBRE, thereby contributing to the circadian rhythmicity of the DAergic system. REV-ERBα controls circadian *TH* gene transcription by recruiting the corepressors N-CoR and HDAC3, which suppress *TH* gene transcription by negatively modifying permissive histone acetylation. SN, substantia nigra; VTA, ventral tegmental area; NAc, nucleus accumbens; DA, dopamine; TH, tyrosine hydroxylase; RORs, retinoic acid receptor-related to orphan nuclear receptors; RRE, ROR/REV-ERB response element; NBRE, NGFI-B response element; N-CoR, nuclear receptor co-repressor 1; HDAC3, histone deacetylase 3; NURR1, nuclear receptor related 1 protein.](molce-40-7-450f1){#f1-molce-40-7-450}

![Comparison of mood-related behaviors and DA levels in vehicle (VEH)- and SR8278 (REV-ERBα antagonist)-injected mice, and VEH- and 6-hydroxydopamine (6-OHDA)-treated mice\
(A) Pharmacological REV-ERBα activity inhibition by microinfusion of SR8278 into the ventral midbrain (VMB) of wild type (WT) mice induced mania-like behaviors, such as decreased depression-and anxiety-like phenotypes at dusk (circadian time 12 h \[CT12\]) with disappearance of daily variation of mood-related behaviors in the tail suspension test (TST) and elevated plus maze test (EPM) ([@b20-molce-40-7-450]). 6-OHDA-treated mice exhibited disruption of daily rhythmic mood-related behaviors toward increased depression- and anxiety-like behaviors at dawn (CT00) in the TST and EPM (unpublished data). \*\*p \< 0.01, CT00 vs. CT12; ††p \< 0.01, VEH vs. SR8278. (B) Microinfusion of SR8278 into the VMB induced a hyperdopaminergic state without daily oscillation of DA, which was caused by loss of the repressive function of REV-ERBα on TH expression. Conversely, 6-OHDA-treated mice showed a hypodopaminergic state owing to DAergic neuronal death in the SNpc. Hyperdopaminergic and hypodopaminergic states can induce mood dysfunction. Therefore, appropriate levels of DA with circadian oscillation may be important to sustain circadian mood-related behaviors.](molce-40-7-450f2){#f2-molce-40-7-450}
